Evidence map›Paper›PMID 29135516›Full record

ArticleThe American journal of surgical pathology2018

International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix.

Simona Stolnicu, Iulia Barsan, Lien Hoang, Prusha Patel, Cristina Terinte, Anna Pesci, Sarit Aviel-Ronen, Takako Kiyokawa, Isabel Alvarado-Cabrero, Malcolm C Pike and 3 more

Abstract readMulticenter Study
In one paragraph

Article in The American journal of surgical pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 192 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
192citing papers in PubMed, 4 pooled it
19.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

192 citing papers in PubMed, 4 syntheses or guidelines pooled it, 394 citations in OpenAlex.

  1. Pooled it
  2. SEOM-GEICO Clinical Guidelines on cervical cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Guideline
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

132 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 7 countries.

Simona StolnicuDepartment of Pathology, University of Medicine and Pharmacy of Targu Mures, Targu Mures.
Iulia BarsanDepartment of Pathology, University of Medicine and Pharmacy of Targu Mures, Targu Mures.
Lien HoangVancouver General Hospital, Vancouver, BC, Canada.
Prusha PatelMemorial Sloan Kettering Cancer Center, New York, NY.
Cristina TerinteRegional Institute of Oncology, Iasi, Romania.
Anna PesciOspedale Sacro Cuore Don Calabria, Negrar, Italy.
Sarit Aviel-RonenDepartment of Pathology, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel.
Takako KiyokawaJikei University School of Medicine, Tokyo, Japan.
Isabel Alvarado-CabreroHospital de Oncología Mexico City, Mexico City, Mexico.
Malcolm C PikeMemorial Sloan Kettering Cancer Center, New York, NY.
Esther OlivaMassachusetts General Hospital, Boston, MA.
Kay J ParkMemorial Sloan Kettering Cancer Center, New York, NY.
Robert A SoslowMemorial Sloan Kettering Cancer Center, New York, NY.
Memorial Sloan Kettering Cancer Center · USUniversitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș · ROVancouver General Hospital · CAHospital General de México · MXInstitutul Regional de Oncologie · ROJikei University School of Medicine · JPOspedale Sacro Cuore Don Calabria · ITSheba Medical Center · IL

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

We sought to classify endocervical adenocarcinomas (ECAs) based on morphologic features linked to etiology (ie, human papillomavirus [HPV] infection), unlike the World Health Organization 2014 classification. The International Endocervical Adenocarcinoma Criteria and Classification (IECC criteria), described herein, distinguishes between human papillomavirus-associated adenocarcinoma (HPVA), recognized by the presence of luminal mitoses and apoptosis seen at scanning magnification, and no or limited HPVA features (nonhuman papillomavirus-associated adenocarcinoma [NHPVA]). HPVAs were then subcategorized based on cytoplasmic features (mostly to provide continuity with preexisting classification schemes), whereas NHPVAs were subclassified based on established criteria (ie, gastric-type, clear cell, etc.). Complete slide sets from 409 cases were collected from 7 institutions worldwide. Tissue microarrays representing 297 cases were constructed; immunohistochemistry (p16, p53, vimentin, progesterone receptor) and chromogenic in situ hybridization using an RNA-based probe set that recognizes 18 varieties of high-risk HPV were performed to validate IECC diagnoses. The 5 most common IECC diagnoses were usual-type (HPVA) (73% of cohort), gastric-type (NHPVA) (10%), mucinous adenocarcinoma of HPVA type, including intestinal, mucinous not otherwise specified, signet-ring, and invasive stratified mucin-producing carcinoma categories (9%), clear cell carcinoma (NHPVA) (3%) and adenocarcinoma, not otherwise specified (2%). Only 3 endometrioid carcinomas were recognized and all were NHPVA. When excluding cases thought to have suboptimal tissue processing, 90% and 95% of usual-type IECC cases overexpressed p16 and were HPV, whereas 37% and 3% of NHPVAs were p16 and HPV, respectively. The 1 HPV gastric-type carcinoma was found to have hybrid HPVA/NHPVA features on secondary review. NHPVA tumors were larger and occurred in significantly older patients, compared with HPVA tumors (P<0.001). The high-risk HPV chromogenic in situ hybridization probe set had superior sensitivity, specificity, and positive and negative predictive values (0.955, 0.968, 0.992, 0.833, respectively) compared with p16 immunohistochemistry (0.872, 0.632, 0.907, 0.545, respectively) to identify HPV-related usual carcinoma and mucinous carcinoma. IECC reliably segregates ECAs into HPVA and NHPVA types using morphology alone. This study confirms that usual-type ECAs are the most common type worldwide and that mucinous carcinomas comprise a mixture of HPVA and NHPVA, with gastric-type carcinoma being the major NHPVA type. Endometrioid and serous carcinomas of the endocervix are extraordinarily rare. Should clinical outcomes and genomic studies continue to support these findings, we recommend replacement of the World Health Organization 2014 criteria with the IECC 2017.

Indexed as

Terminology as TopicAdenocarcinomaBiomarkers, TumorConsensusCyclin-Dependent Kinase Inhibitor p16Diagnosis, DifferentialEndometrial NeoplasmsFemaleHumansImmunohistochemistryIn Situ HybridizationNeoplasm InvasivenessPapillomaviridaePapillomavirus InfectionsPredictive Value of TestsRNA, ViralBiomarkers, TumorCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16RNA, Viral

Identifiers

PMID29135516
PMCPMC5762258
OpenAlexW2769841906

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.